Skip to main content
Equibles
BNGO logo

BNGO · Bionano Genomics, Inc.

Track BNGO — free

Use BNGO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BNGO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.00 -0.04 (-3.85%) At close · Nov 13
Rebalance outlook locked
Going-concern doubt — flagged Nov 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Accordingly, we determined that there is substantial doubt about our ability to continue as a going concern within 12 months after the date that the financial statements included in this Quarterly Report are issued.”
View the 10-Q filed Nov 10, 2026
Market Cap
$13.99M
Shares
13.99M
Volume · Nov 13 557.57K Avg daily vol (3M) 965.62K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.00 Open$1.02 Day$1.00–1.03 52W close$1.00–1.85 Avg vol 30d249K Short int1.4M · 9.9% of shares · 7.4d Short vol47% Last earningsNov 10, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 10

Up next

Next earnings call
Mar 22, 2027 Est · unconfirmed · in 18 wks
Q2 2026 earnings call transcript
call held Aug 10, 2026
Play latest call

Latest documents

2026
Nov 10
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue grows, but substantial doubt raises near-term financing risk

Bionano Genomics reported revenue of $23.1 million, up 13%, and a $22.2 million net loss for the nine months ended September 30, 2026. It faces substantial doubt about going concern and expects additional capital in the very near term.

Revenue $8.28M ▲ 12.3% Net loss $6.45M Diluted EPS -$0.54
Read from the MD&A section
5 source passages
Unless the context requires otherwise, references to “we,” “us,” and “our” refer to Bionano Genomics, Inc. and its subsidiaries or, as the context may require, Bionano Genomics, Inc. only. Total revenue increased by $2.6 million, or 13% to $23.1 million for the nine months ended September 30, 2026, as compared to $20.6 million for the same period in 2025, driven primarily by an increase in instrument, consumables, service and other revenue partially offset by a decrease in software revenue. Our net loss was $6.5 million and $22.2 million for the three and nine months ended September 30, 2026, respectively. Accordingly, based on recurring losses from operations incurred since inception, the expectation of continued operating losses, and the need to raise additional capital to finance our future operations, we determined that there is substantial doubt about our ability to continue as a going concern within 12 months after the date that the financial statements included in this Quarterly Report are issued. Based on our current business plans, we will continue to require additional capital in the very near term to fund our operating expenses and capital expenditure requirements, or we may need to further curtail or cease operations and seek protection by filing a voluntary petition for relief under the United States Bankruptcy Code. Open the document at this passage
Nov 10
Current report 8-K
Revenue rises 12% and guidance stays $31 to $33 million

Bionano Genomics reported third-quarter revenue of $8.3 million, up 12% from $7.4 million, and gross margin of 48%, up from 46%. It reiterated full year 2026 revenue guidance of $31 to $33 million.

Financial results
4 source passages
Reported total revenue of $8.3 million, representing an increase of 12% from $7.4 million in the third quarter of 2025. Generated gross margin of 48%, as compared to 46% for the third quarter of 2025. We anticipate the following results for the full year 2026: Reiterate full year 2026 revenue guidance in the range of $31 to $33 million. Open the document at this passage
Nov 2
Registration statement S-3/A
Registration statement

Bionano Genomics, Inc. established a replacement shelf registration for up to $400,000,000 and disclosed an additional $3,941,645.77 of securities sold under its prior registration statement.

Read from the first part of this long document
Oct 27
Registration statement S-1
Registration statement

Bionano Genomics, Inc. is registering up to 1,332,632 shares issuable upon exercise of outstanding warrants, replacing an expiring registration statement so warrant exercises remain covered. Full exercise would generate approximately $90 million for general corporate purposes.

Read from the first part of this long document
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$31.09M
Trailing 12 months
Net income (TTM)
−$30.11M
Trailing 12 months
Revenue growth YoY
+12.3%
Year over year
Operating margin
-97.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$690,000
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+124.6%
Year over year · more shares
Price change (1Y)
-32.0%
Trailing year
Short interest
9.9%
Latest settlement · 7.4 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▼23.9% $8.16M −$20.12M '24 Q4* ▼26.4% $6.46M −$3.10M '25 Q1 ▼13.4% $6.73M −$6.86M '25 Q2 ▲21.3% $7.37M −$8.50M '25 Q3 ▼2.6% $7.95M −$7.93M '25 Q4* ▲3.6% $6.69M −$8.30M '26 Q1 ▲21.4% $8.17M −$7.42M '26 Q2 LATEST ▲12.3% $8.28M −$6.45M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q2 FY26 earnings call · Aug 10, 2026
Q2 FY26

TL;DR. Bionano reported Q2 2026 revenue of $8.2 million, up 21% year-over-year and above guidance, with record flow cell sales of 9,219 units (+27%), driven by clinical adoption. The company raised the low end of full-year 2026 revenue guidance to $31–$33 million and initiated Q3 guidance of $8.2–$8.6 million, while retiring its senior secured convertible debt.

Bullish
  • + Q2 revenue beat guidance and grew 21% year-over-year to $8.2M, with consumables up 31%
  • + Record flow cell sales of 9,219 units, up 27% year-over-year, driven by clinical adoption
  • + Gross margin reached a record 53% in Q2 2026, up from 52% a year ago
  • + Raised the low end of full-year 2026 revenue guidance to $31–$33M
  • + Fully retired outstanding senior secured convertible debt, simplifying the balance sheet
  • + International revenue now represents the majority of total revenue, reflecting global clinical adoption
Bearish
  • − Top end of full-year 2026 revenue guidance was not raised due to flow cell manufacturing constraints
  • − Demand continues to outpace manufacturing capacity, creating a backlog
  • − Software revenue declined 16% year-over-year on deployment timing delays
  • − Q3 guidance of $8.2–$8.6M implies flat to modest sequential growth despite strong Q2 momentum
  • − Cash runway extends only into Q1 2027, signaling ongoing capital needs

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −18%
below
Price vs 50-day avg −26%
below
RSI (14) 33
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −20%
trailing
6-month return −18%
trailing
YTD return −35%
this year
Relative strength −19%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Accumulating
30 of 36 funds reported for Sep 30 · net +1.6M sh shares · +4 new
Insider flow Accumulating
Net +$9.7K over 90 days · 0% sells
Short interest Rising
9.92% of shares out · ▲ +2.0% MoM · 7.4 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
36 holders — mid 3-yr range
Squeeze score 74
high risk · 0–100
Fundamentals
Strong
Revenue growth +26%
Y/Y
EPS growth +94%
Y/Y
Free cash flow $-16.3M
Quant / Vol
risk profile
Very High
Volatility 64%
annualized · 1-yr
Max drawdown −46%
past year
ATR 9.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 6 of last 8
Latest guidance · from the Earnings Call filed Aug 10, 2026
Revenue · full year 2026 Raised $31M – $33M
May 13, 2026 $30M – $33M changed to Aug 10, 2026 $31M – $33M
prior FY $28.51M midpoint +12.2% Y/Y
Prior guidance period ended · from the 8-K filed Aug 10, 2026
Revenue · Q3 2026 $8.2M – $8.6M
Guided vs delivered · last 8 settled
Revenue Q3 2026
guided $8.2M – $8.6M
$8.28M In line
Revenue Q2 2026
guided $7.5M – $7.8M
$8.17M Beat +6.8%
Revenue Q1 2026
guided $6.5M – $6.7M
$6.69M In line
Q4 2025 revenue Q4 2025
guided $7.5M – $7.9M
$7.95M Beat +3.3%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−18% Bearish
Price vs 50-day avg
−26% Bearish
RSI (14)
33 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Accumulating
30 of 36 funds reported for Sep 30 · net +1.6M sh shares · +4 new
Insider flow Accumulating
Net +$9.7K over 90 days · 0% sells
Short interest Rising
9.92% of shares out · ▲ +2.0% MoM · 7.4 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
36 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $2
vs 200-day avg -18% vs 50-day avg -26%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
adjusted operating expense non-GAAP $8.7M Q2 2026 —
nanochannel array flow cells sold 9,219 Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BNGO
Bionano Genomics, Inc.
this stock
$13.99M -34.6% +26.3% — 9.9%
ISRG
Intuitive Surgical Inc
 $153.77B -21.7% +20.5% 53.8 2.0%
BDX
Becton Dickinson & Co
 $59.39B — +8.2% 96.5 3.0%
MDLN
Medline Inc.
 $51.92B -6.0% +11.5% — 2.9%
ALC
Alcon Inc
 $35.61B -6.0% +10.5% — 3.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
36
% held
16.3%
Reported
30 of 36
Top holder
AIGH Capital Management L…
Held Float
View
Held by Funds
Fund positions
6
View
Short & Settlement
Short Interest Rising
Shares short
1.4M
Days to cover
7.4d
Change
+27.6K sh
View
Short Volume
Short vol %
47%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
1.0K
Value
$1.5K
As of
Oct 8, 2026
View
Off-Exchange
Off-exchange %
61.3%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$9.7K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$28.5M
Net income (FY)
$-26.4M
EPS diluted
$-4.85
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 10, 2026
This year
21

Bionano Genomics reported revenue of $23.1 million, up 13%, and a $22.2 million net loss for the nine months ended September 30, 2026. It faces substantial doubt about going concern and expects additional capital in the very near term.

View
Exempt Offerings
Offering
$20.0M
Filed
Jul 10, 2024
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
Bionano to Report Third Quarter 2…
Published
Oct 27, 2026
View

Performance

5D 20D 120D MTD YTD
BNGO -13.0% -20.0% -18.0% -13.0% -34.6%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -15.6% -18.8% -18.5% -12.9% -45.3%
Key facts CIK 1411690 CUSIP 09075F404 13F (30d) 44 filings 26 filers Visit website Investor relations